Pediatric Glioblastoma Multiforme (GBM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Glioblastoma multiforme (GBM) is a formidable disease, comprising 17% of adult intracranial neoplasms. No identified risk factors are associated with GBM, except for exposure to ionizing radiation. GBM is one of the most aggressive forms of cancer in humans. Despite advancements in surgical techniques and additional treatments, the average survival time remains approximately 1 year. In adults, GBM is the most prevalent type of astrocytoma and is typically associated with a grim prognosis, with a median survival of about 12 months. However, it is rare in children. Around 65% of GBM cases primarily manifest in the cerebral hemispheres, which govern higher cognitive functions such as speech, movement, thought, and sensation. GBMs can also arise in other regions of the brain that regulate sensory perception, temperature sensitivity, balance, and motor function. The most prevalent symptoms of GBM include morning headaches, lethargy, and seizures that vary depending on the type and location of the tumor. Compression of neighboring brain structures due to the tumor's position can result in motor dysfunction, hormonal irregularities, or changes in behavior and cognitive processes. GBMs are typically diagnosed between the ages of 5 and 9, affecting both boys and girls equally. However, they occur more frequently in children with specific genetic syndromes, including neurofibromatosis 1, Li-Fraumeni syndrome, hereditary nonpolyposis colon cancer, and tuberous sclerosis. The majority of GBM cases, however, have an unknown cause. Treatment options for GBM may encompass neurosurgery, radiation therapy, and chemotherapy.

·       Glioblastoma multiforme is the most aggressive malignant primary brain tumor, with an incidence of 2–3 per 100,000 people in the United States and Europe. In children, accounting for only 3% of childhood brain tumors.

Thelansis’s “Pediatric Glioblastoma Multiforme (GBM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pediatric Glioblastoma Multiforme (GBM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Pediatric Glioblastoma Multiforme (GBM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Pediatric Glioblastoma Multiforme (GBM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Pediatric Glioblastoma Multiforme (GBM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032